Tempus Wealth Planning LLC Has $465,000 Position in Haleon plc (NYSE:HLN)

Tempus Wealth Planning LLC raised its position in Haleon plc (NYSE:HLN) by 4.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,813 shares of the company’s stock after acquiring an additional 2,136 shares during the quarter. Tempus Wealth Planning LLC’s holdings in Haleon were worth $465,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Legacy Wealth Asset Management LLC lifted its stake in Haleon by 3.0% in the first quarter. Legacy Wealth Asset Management LLC now owns 70,329 shares of the company’s stock valued at $597,000 after acquiring an additional 2,045 shares during the last quarter. Norden Group LLC raised its position in shares of Haleon by 4,086.3% in the first quarter. Norden Group LLC now owns 428,129 shares of the company’s stock valued at $3,635,000 after purchasing an additional 417,902 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Haleon in the first quarter valued at about $43,000. Founders Financial Securities LLC bought a new position in shares of Haleon in the first quarter valued at about $552,000. Finally, Pinnacle Bancorp Inc. raised its position in shares of Haleon by 29.8% in the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock valued at $53,000 after purchasing an additional 1,421 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Price Performance

Shares of HLN traded up $0.13 during mid-day trading on Thursday, reaching $8.46. The company had a trading volume of 1,761,770 shares, compared to its average volume of 3,326,346. The company’s 50 day simple moving average is $8.41 and its 200 day simple moving average is $8.35. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04. The company has a market capitalization of $38.63 billion, a price-to-earnings ratio of 28.18, a P/E/G ratio of 2.21 and a beta of 0.24.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The company had revenue of $3.70 billion for the quarter, compared to the consensus estimate of $3.71 billion. Analysts expect that Haleon plc will post 0.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. HSBC began coverage on shares of Haleon in a research report on Wednesday, April 17th. They issued a “buy” rating on the stock. Argus reiterated a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. Finally, Berenberg Bank began coverage on shares of Haleon in a research note on Wednesday, June 5th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.